UNASSIGNED: Neutrophil extracellular traps are associated with a unique form of cell death distinct from apoptosis or @entity39 , whereby invading microbes are trapped and killed. Neutrophil extracellular traps can contribute to @entity792 by exposing autoantigens, inducing @entity686 production, and activating the complement system. The association of neutrophil extracellular traps with @entity792 , particularly @entity1252 , will be reviewed. Increased neutrophil extracellular trap formation is seen in @entity1569 , antineutrophil cytoplasmic antibody-associated @entity1333 , @entity1701 @entity309 , and @entity1252 . Neutrophil extracellular traps may promote @entity715 formation in antineutrophil cytoplasmic antibody-associated @entity1333 and @entity1701 . In @entity1252 , increased neutrophil extracellular trap formation is associated with @entity66 activity and @entity8 , suggesting that neutrophil extracellular traps could be a disease activity marker. Neutrophil extracellular traps can damage and kill endothelial cells and promote @entity32 in @entity731 , which may contribute to accelerated @entity731 in @entity1252 . As neutrophil extracellular traps induce @entity686 production, measuring neutrophil extracellular traps may estimate @entity686 levels and identify which @entity1252 @entity1 have elevated levels and may be more likely to respond to emerging anti- @entity686 therapies. In addition to anti- @entity686 therapies, other novel agents, such as @entity898 , DNase I, and peptidylarginine deiminase inhibitor 4, target neutrophil extracellular traps. Neutrophil extracellular traps offer insight into the pathogenesis of @entity792 and provide promise in developing disease markers and novel therapeutic agents in @entity1252 . Priority areas for basic research based on clinical research insights will be identified, specifically the potential role of neutrophil extracellular traps as a biomarker and therapeutic target in @entity1252 .

At the Bedside: Neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal disease'] @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis'] @entity686 :: ('3438', 'Gene') :: ['IFN-a'] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis'] @entity1333 :: ('MESH:D014657', 'Disease') :: ['vasculitis'] @entity66 :: ('MESH:D004194', 'Disease') :: ['increased disease'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis', 'atherosclerotic plaques'] @entity1252 :: ('MESH:D008180', 'Disease') :: ['systemic lupus erythematosus'] @entity898 :: ('MESH:D000111', 'Chemical') :: ['N-acetyl-cysteine'] @entity1701 :: ('MESH:D016736', 'Disease') :: ['antiphospholipid antibody syndrome'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombus'] @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmunity', 'autoimmune diseases'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis']
@entity792 :: (MESH:D001327,Disease) :: ['autoimmune diseases']
